EBOS (ASX: $EBO) 2024 Half Year Results Overview

EBOS (ASX: $EBO) has reported a strong performance for the first half of the 2024 financial year, with a revenue of $6.6 billion, reflecting a 7.1% increase. The underlying earnings per share saw a 6.6% rise to 79.5 cents, and an interim dividend of NZ 57.0 cents per share was declared, marking a 7.5% increase. The company's underlying EBITDA increased by 8.3% to $313.2 million, and the underlying net profit after tax (NPAT) rose by 7.6% to $152.4 million.

Executive Commentary on 2024 Half Year Results

We are pleased with the strong performance in the first half of FY24, driven by continued organic growth and strategic investments. The revenue growth of 7.1% and the increase in underlying EBITDA and NPAT demonstrate the effectiveness of our long-term growth trajectory. Our Healthcare and Animal Care segments have shown robust performances, with Healthcare revenue reaching $6.3 billion and Animal Care generating $286.2 million in revenue. The investments made in the first half align with our strategy of investing for growth, including increased shareholding in Transmedic to 90% and the acquisition of Superior Pet Food Co. We are confident in our ability to continue generating organic earnings growth and pursuing further acquisitions for the remainder of FY24.

Summary of 2024 Half Year Results and Outlook

EBOS has delivered a strong performance in the first half of the 2024 financial year, with significant increases in revenue, underlying EBITDA, and NPAT. The company's Healthcare and Animal Care segments have demonstrated resilience and growth, supported by strategic investments. Looking ahead, EBOS is confident in its ability to continue generating organic earnings growth across both Healthcare and Animal Care, while pursuing further bolt-on acquisitions. The company expects to continue servicing the Chemist Warehouse Australia contract until its expiry in June 2024, after which it does not expect to generate revenue from this contract. With a strong balance sheet, EBOS is well positioned to pursue growth opportunities and modernize its facilities, particularly in New Zealand Healthcare operations.